+ Watch NGSX
on My Watchlist
A biopharmaceutical company, which focused on developing and commercializing novel pain management therapies.
Let's see, how am I going to defend this impulsive green thumb? NeurogesX is garbage, but the last nail isn't in the coffin yet. Having failed to interest physicians and patients in a capsaicin patch, the company is now progressing the development of a capsaicin ointment. Haven't these been around for years? I'm sure there's some important difference I could learn about if I cared.The company's long-term financial picture is dismal (-68M in shareholder equity) but for the short-term they have 34M in available cash plus whatever they were able to scrape together from cheap warrants while I was writing this pitch. Bottom feeders seem eager to push this stub back up to 0.6 or so given the 23% jump today on company PR stating the FDA had agreed to an end of phase II meeting for the capsaicin ointment. I mean, does the FDA often refuse to have a meeting? That's actually considered a catalyst? Whatever. I'm looking for 15-20 pts and then back to the red thumb as we careen towards bankruptcy. If I'm wrong about this leg back up, NeurogesX goes gavel without me.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions